Skip to main content

Table 3 Effects of ERAS on oncologic and long-term outcomes

From: Oncologic and long-term outcomes of enhanced recovery after surgery in cancer surgeries — a systematic review

Outcomes

Study

P value

Findings

Follow-up time

Non-ERAS vs ERAS

OS

Pang et al. [11]

P = 0.9

NS

10 years

Ziegelmueller et al. [12]

P = 0.550

NS

7 years

Oakley et al. [10]

P = 0.57

NS

5 years

Yang et al. [14]

P = 0.007

ERAS improved OS

5 years

Ye et al. [13]

P = 0.066

NS

3 years

Passeri et al. [16]

P = 0.72

NS

2 years

Wang et al. [29]

/

NS

10–20 months

Zhang et al. [30]

P = 0.035

ERAS improved OS

3 years

Quiram et al. [31]

P = 0.464

NS

5 years

Zhu et al. [32]

P = 0.810

NS

1 year

Tian et al. [33]

P = 0.013

ERAS improved OS

5 years

Lohsiriwat et al. [34]

P = 0.014

ERAS improved OS

5 years

CSS

Pang et al. [11]

P = 0.9

NS

10 years

Ziegelmueller et al. [12]

P = 0.725

NS

7 years

Tian et al. [33]

P = 0.033

ERAS improved CSS

5 years

DFS

Passeri et al. [16]

P = 0.38

NS

2 years

Wang et al. [29]

/

NS

10–20 months

Zhang et al. [30]

P = 0.007

ERAS improved DFS

3 years

Quiram et al. [31]

P = 0.272

NS

5 years

Recurrence

Quiram et al. [31]

P = 0.157

NS

3 years

Metastasis

Quiram et al. [31]

P = 0.129

NS

5 years

Life quality

Physical functioning

Liu et al. [15]

P = 0.038

ERAS improved life quality

6 months

Nausea/vomiting

P = 0.048

Motor dysfunction

P = 0.019

RIOT

Failure to RIOT

Day et al. [17]

P = 0.373

NS

/

Days to RIOT

Day et al. [17]

P = 0.134

NS

Lohsiriwat [18]

P = 0.009

ERAS reduced interval to RIOT

Nelson et al. [20]

P = 0.364

NS

Li et al. [21]

P = 0.000

ERAS reduced interval to RIOT

Rate of on time to RIOT

Hassinger et al. [19]

P = 0.022

ERAS improved the on-time initiation of RIOT

Rate of completing RIOT

Nelson et al. [20]

P < 0.001

ERAS improved RIOT completion

High adherence vs low adherence

OS

Gustafsson et al. [23]

P < 0.001

High adherence improved OS

5 years

Lohsiriwat et al. [34]

P = 0.007

High adherence improved OS

5 years

Viannay et al. [22]

P = 0.632

NS

3 years

Pisarska et al. [24]

P = 0.0007

High adherence improved OS

Rubinkiewicz et al. [26]

P = 0.75

NS

Passeri et al. [16]

P = 0.14

NS

2 years

CSS

Gustafsson et al. [23]

P = 0.020

High adherence improved CSS

5 years

DFS

St-Amour et al. [25]

P = 0.000

High adherence improved DFS

3 years

Passeri et al. [16]

P = 0.81

NS

2 years

Survival of metastasis

Viannay et al. [22]

P = 0.668

NS

3 years

Local recurrence

Gustafsson et al. [23]

P = 0.211

NS

5 years

Days to RIOT in young patients

St-Amour et al. [25]

P = 0.001

High adherence reduced interval to RIOT

3 years

Alteration of single item within ERAS protocol

OS

Curtis et al. [27]

P = 0.009

Laparoscopy surgery improved OS

5 years

Wang et al. [29]

/

NS

10–20 months

DFS

Wang et al. [29]

/

NS

10–20 months

Local recurrence

Asklid et al. [28]

P = 0.981

NS

5 years

OD

P = 0.006

Restrictive fluid therapy improved survival

CSD

P = 0.008

Days to RIOT

Kato et al. [35]

P = 0.08

NS

/

  1. OS overall survival, CSS cancer-specific survival, DFS disease-free survival, RIOT return to intended oncologic therapy, OD overall death, CSD cancer-specific death, NS no significance